Clinical Report: Pulmonary Infections in Lung Cancer Patients on ICIs

Overview

This study investigates the incidence and risk factors of pulmonary infections in lung cancer patients undergoing treatment with immune checkpoint inhibitors (ICIs). Findings indicate a significant occurrence of infections, particularly pulmonary, highlighting the need for vigilant monitoring and management strategies.

Background

The use of immune checkpoint inhibitors has revolutionized lung cancer treatment, but they also pose risks of immune-related adverse events, including pulmonary infections. Understanding the epidemiology and risk factors for these infections is crucial for optimizing patient care and improving outcomes in this vulnerable population.

Data Highlights

No numerical data was provided in the source material.

Key Findings

• 7.3% of melanoma patients treated with ICIs experienced severe infections.
• 18% of ICI-treated patients developed infections, with pulmonary infections constituting 58.3% of cases.
• 19.2% of NSCLC patients on ICIs had infectious complications, predominantly bacterial.
• Diabetes mellitus was identified as a significant risk factor for infections in ICI-treated patients.
• Mortality rates increased with infection frequency, rising from 10.7% to 40%.

Clinical Implications

Clinicians should maintain a high index of suspicion for pulmonary infections in lung cancer patients receiving ICIs, especially those with comorbidities like diabetes. Prompt evaluation and management of new respiratory symptoms are essential to differentiate between immune-related pneumonitis and infections.

Conclusion

The findings underscore the importance of monitoring for pulmonary infections in lung cancer patients treated with ICIs, necessitating proactive strategies to mitigate risks and enhance patient safety.

References

1. Ogishi et al, Immunity, 2024 -- Study May Illuminate Cause of Common Checkpoint Inhibitor Adverse Effect
2. Riaz et al, JCO Oncology Practice, 2025 -- Are Immune Checkpoint Inhibitors Effective in Hospitalized Patients With Cancer?
3. Naqash et al, Journal of Clinical Oncology, 2022 -- Incidence of Major Adverse Cardiac Events in Patients Receiving Immune Checkpoint Inhibitors
4. NCCN GUIDELINES® INSIGHTS, 2024 -- Management of Immunotherapy-Related Toxicities
5. BMC Cancer, 2025 -- Incidence and risk factors of serious infections occurred in patients with lung cancer following immune checkpoint blockade therapy
6. the asco post — Studies Explore Cardiac Risks and Clinical Characteristics Associated With Immune Checkpoint Inhibitor–Related Myocarditis
7. NCCN Guidelines Insights
8. Management of toxicities from immunotherapy
9. Incidence and risk factors of serious infections occurred in patients with lung cancer following immune checkpoint blockade therapy